Packing a Punch against PD-L1
- PMID: 35652219
- DOI: 10.1158/2159-8290.CD-22-0301
Packing a Punch against PD-L1
Abstract
Antibodies targeting immune checkpoints have made major advances in cancer therapy, but their use can be limited by immune-related adverse effects. The introduction of small-molecule immune-checkpoint inhibitors represents an alternative to improve the current antibody-based immune therapies. See related article by Koblish et al., p. 1482 (3).
©2022 American Association for Cancer Research.
Comment on
-
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156. Cancer Discov. 2022. PMID: 35254416 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
